ARRIGO ARRIGONI, M.D.; ANTONIO PONZETTO, M.D.; GIOVANNI ACTIS, M.D.; FERRUCCIO BONINO, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: A cause of liver damage in carriers of hepatitis B surface antigen (HBsAg) is the newly described hepatitis B virus-associated delta agent (1); delta hepatitis may be a progressive disease, unresponsive to steroids and immunosuppressors (2). We studied whether levamisole, a drug restoring peripheral lymphocyte function in patients with impaired cellular immunity (3), may be beneficial in patients with chronic delta hepatitis.
A pilot study was done in 16 carriers of hepatitis B virus with chronic active hepatitis, 8 with intrahepatic hepatitis B core antigen, (HBcAg) and 8 with delta antigen detected by immunofluorescence. Ten patients were
ARRIGONI A, PONZETTO A, ACTIS G, et al. Levamisole and Chronic Delta Hepatitis. Ann Intern Med. 1983;98:1024. doi: https://doi.org/10.7326/0003-4819-98-6-1024_1
Download citation file:
Published: Ann Intern Med. 1983;98(6):1024.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use